(Shutterstock) (Shutterstock)
Israel anti-rabies vaccine

Israeli biotech Kamada has launched a anti-Rabies vaccine in 10 countries, and Israel’s CollPlant announced positive final trial results for a gel designed for the treatment of chronic, hard to heal wounds and surgical wounds.

By: Michael Ordman



Rabies vaccine is ready for US market

Following successful trials, Israeli biotech Kamada has launched its KamRAB anti-Rabies vaccine in 10 countries, including Israel. Kamada will now apply for a Biologics License Application (BLA) from the US FDA – the last step before offering a remedy for sale in the United States.

Collagen wound treatment final trials success

Israel’s CollPlant announced positive final trial results for Vergenix FG (Flowable Gel), designed for the treatment of chronic, hard to heal wounds and surgical wounds. 4 weeks after a single application, average wound closure was 80% with 45% fully closed.

Blood test for Alzheimer’s

Israeli biotech NeuroQuest is to begin clinical trials of its blood test for early diagnosis of Alzheimer’s disease. Human trials in Israel have already proved 87% accurate – with blood tests, anything over 70% is considered medically significant.

Non-implant heart valve treatment

Israel’s Pi-Cardia has developed the Leaflex Catheter System – a novel non-implant based technology for treating patients with aortic valve stenosis, rather than replacing the heart valve. Pi-Cardia has just raised $10 million to help complete development of a second-generation device.

Faster diagnosis of a heart attack

Dr Amos Danielli, now of Israel’s Bar Ilan University, developed technology at Tel Aviv University to identify minute quantities of chemicals using magnetic particles attached to fluorescent molecules. One use is to detect the protein Troponin, an indicator of an imminent heart attack. Dr Danielli has founded the company MagBiosense which has won a NIS 900,000 grant from the BIRD foundation.


Israel hosts emergency response conference

Israel hosted hundreds of delegates from 30 countries, plus the World Health Organization, at the Fourth Israeli International Conference on Healthcare System, Preparedness and Response to Emergencies and Disasters in Tel Aviv and Beersheva.

Helping us get to 120

Israeli-born Technion graduate Dr Nir Barzilai is now director of the Institute for Aging Research at the Albert Einstein College of Medicine in New York. As he approaches his 60th birthday himself, he is working with the US FDA on treatments that could make everyone live a lot longer.


Click here for all of this week’s Good News from Israel.